BRPI0719182A2 - Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b - Google Patents

Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b

Info

Publication number
BRPI0719182A2
BRPI0719182A2 BRPI0719182-0A2A BRPI0719182A BRPI0719182A2 BR PI0719182 A2 BRPI0719182 A2 BR PI0719182A2 BR PI0719182 A BRPI0719182 A BR PI0719182A BR PI0719182 A2 BRPI0719182 A2 BR PI0719182A2
Authority
BR
Brazil
Prior art keywords
dislipidemic
omega
levels
agent
fatty acids
Prior art date
Application number
BRPI0719182-0A2A
Other languages
English (en)
Inventor
Roelof M L Rongen
Robert A Shalwitz
Douglas Kling
Ralph T Doyle Jr
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of BRPI0719182A2 publication Critical patent/BRPI0719182A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0719182-0A2A 2006-10-10 2007-10-10 Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b BRPI0719182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85028006P 2006-10-10 2006-10-10
PCT/US2007/021631 WO2008045465A1 (en) 2006-10-10 2007-10-10 Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels

Publications (1)

Publication Number Publication Date
BRPI0719182A2 true BRPI0719182A2 (pt) 2014-10-21

Family

ID=39283166

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719182-0A2A BRPI0719182A2 (pt) 2006-10-10 2007-10-10 Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b

Country Status (10)

Country Link
EP (1) EP2089014A4 (pt)
JP (1) JP2010505956A (pt)
KR (1) KR20090080070A (pt)
CN (2) CN101553221A (pt)
AU (1) AU2007307007A1 (pt)
BR (1) BRPI0719182A2 (pt)
CA (1) CA2672919A1 (pt)
EA (2) EA018734B1 (pt)
MX (1) MX2009003921A (pt)
WO (1) WO2008045465A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2008088415A1 (en) * 2006-10-18 2008-07-24 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids for reduction of lp-pla2 levels
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
ES2768091T3 (es) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
BR112014032905B1 (pt) 2012-06-29 2022-02-22 Amarin Pharmaceuticals Ireland Limited Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
JP6227535B2 (ja) * 2012-08-30 2017-11-08 株式会社三和化学研究所 脂質異常症の予防又は治療薬
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2938718C (en) * 2014-02-05 2022-10-18 Dezima Pharma B.V. Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019349563B2 (en) 2018-09-24 2023-06-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170643A1 (en) * 1999-10-26 2003-09-11 Edward Fisher Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
EP1919468A4 (en) * 2005-07-18 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF

Also Published As

Publication number Publication date
EA018734B1 (ru) 2013-10-30
AU2007307007A1 (en) 2008-04-17
CN101553220A (zh) 2009-10-07
EP2089014A1 (en) 2009-08-19
EA200970360A1 (ru) 2009-10-30
MX2009003921A (es) 2009-08-31
EA200970359A1 (ru) 2009-10-30
CA2672919A1 (en) 2008-04-17
KR20090080070A (ko) 2009-07-23
JP2010505956A (ja) 2010-02-25
CN101553221A (zh) 2009-10-07
EP2089014A4 (en) 2009-12-09
WO2008045465A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
BRPI0719182A2 (pt) Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b
ZA201003030B (en) Medium-chain length fatty acids and glycerides as nephroprotection agents
EP2083815A4 (en) STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCING APO-B MIRRORS
BRPI0921467A2 (pt) Enzimas e métodos para produzir ácidos graxos ômega-3
DK1385498T3 (da) Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler
IL210233A0 (en) Omega 3 fatty acid formulations
EP1723096A4 (en) TRIGLYCERIDES STRUCTURES AND EMULSIONS CONTAINING THESE TRIGLYCERIDES
EP1830830A4 (en) OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC MEANS FOR LIPID THERAPY
CL2007003761A1 (es) Composicion liquida de limpieza personal que comprende isetionatos de acilo graso, cosurfactante, alcanolamida y/o alquilaminaoxido, acidos grasos de cadena recta o mezcla con alcoholes grasos de cadena recta y/o aceites de hidrocarburo alifatico, la
BRPI0717027A2 (pt) Hidrocarbonetos e ácidos graxos de cadeias de comprimento médio de algas
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0911606A2 (pt) Polipeptídeo e métodos para produzir triacilgliceróis compreendendo ácidos graxos modificados
BRPI0719594A2 (pt) Partícula de liberação contendo agente de benefício
DE502005004091D1 (de) Emulsionen mit ungesättigten Fettsäuren und deren Estern
BRPI0816640A2 (pt) "método para produzir produtos de proteína estável ácida e produtos assim produzidos"
BRPI0819026A2 (pt) "método para produzir um gel aquoso de adapaleno e gel aquoso de adapaleno"
PT1418225E (pt) Agente desinfectante e desodorizante para sanitas
IL190728A0 (en) Intravenous essential fatty acid emulsion
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
PL1765318T3 (pl) Średniołańcuchowe kwasy tłuszczowe przydatne jako środki przeciwdrobnoustrojowe
ITMI20051371A1 (it) Dispositivo e procedimento per la tempra termica di oggetti oblunghi cavi
CL2011000290A1 (es) Método para extraer ácidos grasos poliinsaturados de cadena larga; composición de aceite y su uso en tratamiento cosméticos o terapéuticos.
BRPI0813074A2 (pt) "processo de preparação de ésteres de ácidos graxos e processo de preparação de bagaços"
BRPI0916672A2 (pt) método para fabricação de um núcleo absorvente tendo uma pluralidade de primeiras regiões e uma segunda região circundando cada uma das primeiras regiões
CL2004001004A1 (es) Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 60/850,280 DE 10/10/2006 REIVINDICADA NO PCT/US2007/021631, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. OBSERVA-SE QUE A PRIORIDADE US 60/850,280 DE 10/10/2006 POSSUI COMO TITULAR "ROELOF M. L. RONGEN" E "ROBERT A. SHALWITZ". ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("RELIANT PHARMACEUTICALS, INC.") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]